| 03.10.25 | Novo’s underwhe lming CagriSema sends stock d own 10%; Amgen starry-eyed with Rocket's double ph. 3 wins

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

Gestern um 16:36

Html
Text

Webinar: Data driven targeting in HCP education: Engaging physicians within critical treatment decision window

Wednesday, March 26, 2025 | 12pm ET / 9am PT

Join us for this exclusive webinar to gain actionable insights from industry experts on the top challenges of HCP engagement and latest strategies for driving commercial success. Register today.

Today’s Big News

Mar 10, 2025

Novo Nordisk links CagriSema to 16% weight loss, sending stock down again

Amgen ignites Rocket program with phase 3 wins for $400M eczema prospect

J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu in pair of phase 3 trials

Mineralys’ stock jumps as hypertension drug posts double clinical wins

Agomab’s ALK5 inhibitor hits target in phase 2 Crohn’s disease trial

Nasdaq stock market plans move to 24-hour trading

NIH unveils plan to centralize grant reviews in effort to save $65M+ annually

Arrowhead finds RNAi kidney disease candidate is well tolerated in phase 1/2 IgAN trial cohort

Webinar: Enhancing Speed and Precision in Developability Assessment

Wednesday, March 26, 2025 | 2pm ET / 11am PT

Understanding a molecule’s characteristics early in development helps minimize challenges and streamline the path to manufacturing. This webinar will explore key considerations in developability assessment, the role of in silico tools in molecular evaluation, and strategies for improving data security in the process. Register now to join us.

Featured

Novo Nordisk links CagriSema to 16% weight loss, sending stock down again

By Nick Paul Taylor

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. Three months after missing that target in its first phase 3 CagriSema trial, the Danish drugmaker has fallen even further short of that bar in the second study.

Amgen ignites Rocket program with phase 3 wins for $400M eczema prospect

By Nick Paul Taylor

The data drops provide more evidence that rocatinlimab improves outcomes in atopic dermatitis, but questions about the positioning of the anti-OX40 antibody versus Sanofi and Regeneron’s Dupixent remain unanswered.

J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu in pair of phase 3 trials

By James Waldron

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a pair of phase 3 trials.

Mineralys’ stock jumps as hypertension drug posts double clinical wins

By James Waldron

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of hypertension.

Webinar: A New Era for Medication Access

Thursday, March 27, 2025 | 3pm ET / 12pm PT

The way healthcare providers are navigating medication access is evolving rapidly, making it critical for pharma brands to keep up. Join us for this deep dive into the latest strategies and tools that can be seamlessly integrated into HCP workflows, while also driving efficiency, improved patient outcomes, and measurable impact. Register now.

Agomab’s ALK5 inhibitor hits target in phase 2 Crohn’s disease trial

By James Waldron

Agomab’s ALK5 inhibitor has proven its ability to target the correct part of the intestine in a phase 2 trial of fibrostenosing Crohn’s disease.

Nasdaq stock market plans move to 24-hour trading in US

By Gabrielle Masson

Nasdaq plans to roll out 24-hour trading for U.S. companies in a move designed to modernize the market.

NIH unveils plan to centralize grant reviews in effort to save $65M+ annually

By Darren Incorvaia

The National Institutes of Health unveiled a plan on March 6 to move the peer review of grant applications, cooperative agreements and research and development contracts to a central location at the agency’s Center for Scientific Review (CSR).

Arrowhead finds RNAi kidney disease candidate is well tolerated in phase 1/2 IgAN trial cohort

By Gabrielle Masson

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was generally well tolerated among 14 patients with kidney disease.

On the heels of FDA nod for cancer drug, Sun Pharma buys Checkpoint Therapeutics for up to $416M

By Angus Liu

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer.

All HHS employees offered $25K voluntary buyout offer: media reports

By Noah Tong

HHS employees, a workforce about 80,000 strong, were notified Friday of the option to voluntarily resign in exchange for a $25,000 payment, multiple media outlets reported.

Neurotech nabs FDA approval to treat rare eye disorder with cell therapy implant Encelto

By Fraiser Kansteiner

The FDA last week approved Neurotech’s cell therapy implant revakinagene taroretcel to treat the vision-robbing neurodegenerative disease macular telangiectasia type 2. The therapy, which will adopt the brand name Encelto, is the first to win the FDA’s blessing in the rare vision disorder.

Fierce podcasts

Don’t miss an episode

A look at biotech's biggest money raisers of 2024

This week on "The Top Line," we dig into several of the biggest private funding rounds in biotech last year and discuss the shifting VC landscape.

What’s next for digital health investing in 2025?

Research reveals ‘ticking DNA clock’ behind Huntington’s disease

Webinar: Nonviral CRISPR-based knock-in of chimeric antigen receptor transgenes into T cells for cell therapy

Thursday, April 3, 2025 | 11am ET / 8am PT

Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT (Cleaved, Linearized with Protein Template) technology. Learn more about this groundbreaking technology designed to improve the efficiency of genome editing. Register now.

Resources

Whitepaper

The Oncology Market: 2025 Outlook

Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Redefining vaccine trial recruitment

Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials.

Sponsored by: Avacare Clinical Research Network

Whitepaper